ALFERON N INJECTION
LOE Approachinginterferon alfa-n3
BLAVIAL
Approved
Oct 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALFERON N INJECTION is a human leukocyte interferon alfa-N3 biologic approved in 1989 for viral and neoplastic indications. It is a natural interferon product derived from human leukocytes that activates immune responses against infected or malignant cells. The product is administered by injection and represents an older generation interferon therapy.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), this brand is likely in portfolio maintenance mode with minimal new hiring or expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection
HIV Infections
Career Relevance
ALFERON N has zero linked job openings, reflecting its mature status and limited commercial expansion. Career opportunities are concentrated in portfolio maintenance, regulatory compliance, and transition management rather than growth-oriented roles.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.